Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | SCD | O00767 | 2/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113344 | 0.91 | ACHE (0.44) | ACHEUSP30BCHESCDSCD5 | |
| SCHEMBL4115130 | 0.91 | ACHE (0.45) | ACHEBCHESCD5CHRM4 | |
| SCHEMBL4121129 | 0.89 | CETP (0.41) | ACHEUSP30MGLL | |
| SCHEMBL4133873 | 0.89 | ACHE (0.44) | ACHEBCHE | |
| SCHEMBL4130230 | 0.88 | ACHE (0.42) | ACHEUSP30BCHESCDSCD5 | |
| Dimethylamine SCHEMBL4113352 | 0.87 | ACHE (0.45) | ACHEUSP30BCHESCDSCD5 | |
| SCHEMBL4112092 | 0.86 | ACHE (0.42) | ACHEUSP30BCHE | |
| SCHEMBL4113639 | 0.85 | ACHE (0.47) | ACHEUSP30BCHE | |
| SCHEMBL4133580 | 0.84 | ACHE (0.39) | ACHEBCHESCDSCD5 | |
| SCHEMBL4133717 | 0.83 | ACHE (0.47) | ACHEBCHEMGLLCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | ACHE 3716/4885USP30 4343/4885BCHE 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.